ImmunityBio (IBRX) earnings history
Most recent quarter
- Fiscal period
- Q4 2025
- Period end
- Dec 31, 2025
- EPS actual
- −$0.06
- EPS estimate
- −$0.08
- EPS surprise
- +21.57%
- Revenue surprise
- −0.20%
- Revenue
- $38.3M
- Revenue estimate
- $38.4M
- Reported
- Feb 23, 2026
ImmunityBio reported Q4 2025 results on February 23, 2026. The company posted a loss of $0.06 per share, narrower than the expected loss of $0.08, a 21.57% beat. Revenue was $38.3 million, in line with the $38.4 million estimate. A year earlier, in Q4 2024, the loss was $0.09 per share and revenue $7.6 million, so revenue was about five times higher.
Every quarter in the table is a loss, but the losses have narrowed. The full-year loss shrank from $1.14 per share in 2023 to $0.63 in 2024. The deepest quarterly loss shown was $0.36 in Q4 2023, and Q4 2025 was the smallest. Revenue was below $0.5 million a quarter through 2023, then rose to $16.5 million in Q1 2025, $26.4 million in Q2 2025 and $38.3 million in Q4 2025. The record is patchy: there is no Q3 2025 row, and only single quarters appear for 2020 and 2022. ImmunityBio beat the EPS estimate in 5 of the 13 quarters shown, with one exactly in line.
The table holds no results after Q4 2025. In past years, first-quarter results came in May and third-quarter results in early to mid November.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2025 | Feb 23, 2026 | −$0.08 | −$0.06 | +21.57% | $38.3M | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.11 | −$0.10 | +7.41% | $26.4M | SEC |
| Q1 2025 | May 12, 2025 | −$0.13 | −$0.15 | −17.19% | $16.5M | SEC |
| Q4 2024 | Mar 3, 2025 | −$0.20 | −$0.09 | +55.00% | $7.6M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.18 | −$0.14 | +21.35% | $6.1M | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.16 | −$0.20 | −25.00% | $1.0M | SEC |
| Q1 2024 | May 9, 2024 | −$0.20 | −$0.20 | −2.56% | $0.00 | SEC |
| Q4 2023 | Mar 19, 2024 | −$0.18 | −$0.36 | −100.00% | $119,500.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.26 | −$0.19 | +25.49% | $82,000.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.24 | −$0.32 | −36.17% | $41,000.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.27 | −$0.27 | +0.00% | $400,000.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.22 | −$0.26 | −18.18% | $14,000.00 | — |
| Q1 2020 | May 11, 2020 | −$0.17 | −$0.19 | −11.76% | $21,000.00 | — |
Quarterly revenue
Frequently asked questions
When did ImmunityBio (IBRX) last report earnings?
ImmunityBio last reported on Feb 23, 2026, covering fiscal Q4 2025.
Did IBRX beat earnings estimates?
Yes. ImmunityBio reported EPS of −$0.06 for Q4 2025 against a −$0.08 estimate — a 21.57% beat.
How much revenue did IBRX report last quarter?
ImmunityBio reported $38.3M in revenue for Q4 2025, against a consensus estimate of $38.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.